AllSight
Companies · PBLS · Pharmaceutical Preparations
Parabilis Medicines, Inc. (PBLS)
Parabilis Medicines, Inc. (PBLS) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Sep 15, 2026ESMO data presentation
Parabilis Medicines sets ESMO zolucatetide data reveal, but offers no results yet
Sep 2, 2026CMO departure
Parabilis Medicines loses CMO Benzaghou, with no successor named
Aug 25, 2026Tendler appointed
Parabilis Medicines adds J&J oncology veteran to board, but no clinical catalyst follows
Aug 13, 2026$125M Regeneron collaboration
The $125M deal is old news; October’s desmoid data is the real test
Related companies in Pharmaceutical Preparations
About AllSight · Editorial standards & method · Contact